Unknown

Dataset Information

0

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.


ABSTRACT: To project the clinical and economic outcomes of a genotype assay for selection of third-line antiretroviral therapy (ART) in resource-limited settings, as per the planned international A5288 trial (MULTI-OCTAVE).We used the Cost-effectiveness of Preventing AIDS Complications (CEPAC)-International Model to compare three strategies for patients who have failed second-line ART in South Africa: sustained second-line: no genotype assay, all patients remain on second-line ART; A5288: genotype to determine the resistance profile and assign an appropriate regimen; or population-based third-line: no genotype, all patients switch to a potent third-line regimen. Model inputs are from published data in South Africa. Resistance profiles, ART regimens, and efficacy data were those used for trial planning.Projected life expectancy for sustained second-line, A5288, and population-based third-line are 61.1, 103.8, and 104.2 months. Compared to sustained second-line ($12?,460), per person lifetime costs increase for the A5288 ($39,?250) and population-based ($44,?120) strategies. The incremental cost-effectiveness ratio of A5288, compared to sustained second-line, is $7500/year of life saved (YLS), and for population-based third-line, compared to A5288, is $154?,500/YLS. In the A5288 strategy, very late presentation to care, coupled with lengthy delays to obtain the genotype, dramatically reduces 5-year survival, making the population-based third-line strategy more attractive.We project that, whereas the public health approach to third-line therapy is unaffordable, genotype assays and third-line ART in resource-limited settings will increase survival and be cost-effective compared to the population-based approach, supporting the value of an efficacy study.

SUBMITTER: Lorenzana SB 

PROVIDER: S-EPMC3424271 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.

Lorenzana Sarah B SB   Hughes Michael D MD   Grinsztejn Beatriz B   Collier Ann C AC   Luz Paula Mendes PM   Freedberg Kenneth A KA   Wood Robin R   Levison Julie H JH   Mugyenyi Peter N PN   Salata Robert R   Wallis Carole L CL   Weinstein Milton C MC   Schooley Robert T RT   Walensky Rochelle P RP  

AIDS (London, England) 20120601 9


<h4>Objectives</h4>To project the clinical and economic outcomes of a genotype assay for selection of third-line antiretroviral therapy (ART) in resource-limited settings, as per the planned international A5288 trial (MULTI-OCTAVE).<h4>Methods</h4>We used the Cost-effectiveness of Preventing AIDS Complications (CEPAC)-International Model to compare three strategies for patients who have failed second-line ART in South Africa: sustained second-line: no genotype assay, all patients remain on secon  ...[more]

Similar Datasets

| S-EPMC5861504 | biostudies-literature
| S-EPMC9769697 | biostudies-literature
| S-EPMC8298588 | biostudies-literature
| S-EPMC6855441 | biostudies-literature
| S-EPMC4220801 | biostudies-other
| S-EPMC3809900 | biostudies-literature
| S-EPMC6100767 | biostudies-literature
| S-EPMC4169284 | biostudies-literature
| S-EPMC3948456 | biostudies-literature
| S-EPMC3526495 | biostudies-literature